Large study reveals Real-World outcomes of immunotherapy in advanced kidney cancer
NCT ID NCT05858749
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of 494 adults with advanced kidney cancer who received immunotherapy as their first treatment. Researchers looked at how long patients stayed on treatment, how they responded, and survival rates. The goal was to understand which treatment combinations work best in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
494 people
The number who actually took part.
- Started
-
Jun 2022
- Finished
-
Nov 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This is a retrospective, longitudinal cohort study that involves the analysis of data collected through the IMDC database from selected academic clinical sites participating in this study.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosed with mRCC * Age 18 years or over at the time of mRCC diagnosis * Received IO combination treatment in 1L such as receiving ipilimumab + nivolumab or an axitinib-based regimen (ie, axitinib + pembrolizumab or axitinib + avelumab) as 1L * Received subsequent treatments following 1L (e.g., 2L, 3L) * Actively treated at an IMDC clinical center (to avoid incomplete data) Exclusion Criteria: \- There are no exclusion criteria for this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic renal cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Headquarters
New York, New York, 10017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a PET scan reveal who will respond to kidney cancer therapy?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Radiation boosts immunotherapy in kidney cancer trial
- Immunotherapy duo shows promise in kidney cancer battle